Key Points
June 29 (Reuters) - The director of the U.S. Centers for Disease Control and Prevention on Thursday signed off on the use of new vaccines from Pfizer (PFE.N) and GSK (GSK.L) to prevent severe respiratory syncytial virus (RSV) infections in older adults...
CDC Director Rochelle Walensky endorsed agency advisers' recommendation that adults aged 60 or older get the shots, but stopped short of saying all of that population should get one of the vaccines...
The vaccines are the first approved to prevent RSV, which causes around 14,000 deaths in adults aged 65 and older in the U.S. annually, according to government estimates..
Both Pfizer and GSK presented data at the meeting suggesting the shots could be protective for at least two years, but the additional protection could mean higher prices because of the additional benefit to the health system..
The U.S. Food and Drug Administration in May approved the first of the RSV vaccines, from GSK and branded as Arexvy, and later Pfizer's Abrysvo, for people aged 60 and older...
